These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 22699206)

  • 1. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT.
    Yoneyama T; Tateishi U; Endo I; Inoue T
    Eur J Radiol; 2014 Oct; 83(10):1734-9. PubMed ID: 25043494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
    Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
    Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
    Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
    HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data.
    Smeets P; Ham H; Ceelen W; Boterberg T; Verstraete K; Goethals I
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):327-32. PubMed ID: 20639817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.